Loading
Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease.
Iberdomide is a cereblon E3 ligase modulator (CELMoD) that binds cereblon with around 20-fold higher affinity than lenalidomide, degrading Ikaros and Aiolos more completely and so killing myeloma cells and stimulating T cells more potently. Because it acts through the same pathway with greater force, it is active in lenalidomide-refractory disease: in CC-220-MM-001 the doublet with dexamethasone gave an ORR of about 26%, higher in combinations. Its main development is as post-transplant maintenance, where the phase 3 EXCALIBER-Maintenance trial against lenalidomide met its primary endpoint according to BMS reports in 2026, and in relapsed disease, where EXCALIBER-RRMM (Iber-Dd versus Dara-Vd) is ongoing. It is a more powerful successor to lenalidomide aiming to keep myeloma in remission longer after transplant.
Binds cereblon with ~20-fold higher affinity than lenalidomide, degrading Ikaros/Aiolos more completely.
1.Iberdomide binds its target with one end and an E3 ubiquitin ligase with the other.
Compare all products across the US, EU, UK, Japan, China and Australia →
In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma The confirmatory requirement was still open 0.1 years later, when the FDA's table was read. source
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effective 13 August 2026) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Iberdomide" OR ABSTRACT:"Iberdomide" OR TITLE:"Zenbexus" OR ABSTRACT:"Zenbexus" OR TITLE:"CC-220" OR ABSTRACT:"CC-220") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iberdomide, not a curated reading list.
Shares A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe, Cereblon E3 ligase modulators (CELMoDs), Ubiquitin-proteasome system & protein homeostasis, Relapsed or refractory multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Ubiquitin-proteasome system & protein homeostasis, Lenalidomide, Relapsed or refractory multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Lenalidomide, Relapsed or refractory multiple myeloma, Multiple myeloma.